Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-VEGF Strategy for NVG Secondary to PDR
NCT05156021Completed
- Sponsor
- Ruijin Hospital
- Start
- Dec 2021
- Primary completion
- Dec 2022
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label trial of ranibizumab in neovascular glaucoma (NVG) and proliferative diabetic retinopathy (PDR), sponsored by Ruijin Hospital. Primary endpoints: Best Corrected Visual Acuity at 12 months and Intraocular Pressure at 12 months. Started Dec 2021; status: completed.
02
Drugs
ranibizumab
03
Conditions
neovascular glaucoma (NVG)proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT05156021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05156021.